These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23150894)

  • 1. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.
    Fattore G; Torbica A; Susi A; Giovanni A; Benelli G; Gozzo M; Toso V
    BMC Neurol; 2012 Nov; 12():137. PubMed ID: 23150894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of patients admitted to stroke units in Spain.
    Alvarez-Sabín J; Quintana M; Masjuan J; Oliva-Moreno J; Mar J; Gonzalez-Rojas N; Becerra V; Torres C; Yebenes M;
    Eur J Health Econ; 2017 May; 18(4):449-458. PubMed ID: 27084749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain.
    Lopez-Bastida J; Oliva Moreno J; Worbes Cerezo M; Perestelo Perez L; Serrano-Aguilar P; Montón-Álvarez F
    BMC Health Serv Res; 2012 Sep; 12():315. PubMed ID: 22970797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
    López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():109-17. PubMed ID: 27038626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].
    Marcellusi A; Viti R; Incorvaia C; Mennini FS
    Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.
    López-Bastida J; Linertová R; Oliva-Moreno J; Posada-de-la-Paz M; Serrano-Aguilar P; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Baji P; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():99-108. PubMed ID: 27038627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
    Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
    Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation.
    Gerzeli S; Tarricone R; Zolo P; Colangelo I; Busca MR; Gandolfo C
    Neurol Sci; 2005 Jun; 26(2):72-80. PubMed ID: 15995823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Return to work after specialised burn care: A two-year prospective follow-up study of the prevalence, predictors and related costs.
    Goei H; Hop MJ; van der Vlies CH; Nieuwenhuis MK; Polinder S; Middelkoop E; van Baar ME;
    Injury; 2016 Sep; 47(9):1975-82. PubMed ID: 27085837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
    Chuvarayan Y; Finger RP; Köberlein-Neu J
    Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
    Iskrov G; Astigarraga I; Stefanov R; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Schieppati A; Taruscio D; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():67-78. PubMed ID: 27042831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical resource use and costs of health care after acute stroke in Germany.
    Rossnagel K; Nolte CH; Muller-Nordhorn J; Jungehulsing GJ; Selim D; Bruggenjurgen B; Villringer A; Willich SN
    Eur J Neurol; 2005 Nov; 12(11):862-8. PubMed ID: 16241975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.
    Mennini FS; Sciattella P; Marcellusi A; Toraldo B; Koch M
    Dig Liver Dis; 2017 Sep; 49(9):1003-1008. PubMed ID: 28663067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of COPD in Italy: results from the Confronting COPD survey.
    Dal Negro R; Rossi A; Cerveri I
    Respir Med; 2003 Mar; 97 Suppl C():S43-50. PubMed ID: 12647942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health related quality of life, service utilization and costs for patients with Huntington's disease in Norway.
    van Walsem MR; Frich JC; Gómez Castañeda M; Howe EI; Pihlstrøm L; Andelic N; Aas E
    BMC Health Serv Res; 2022 Dec; 22(1):1527. PubMed ID: 36517848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011.
    Mangen MJ; Bouwknegt M; Friesema IH; Haagsma JA; Kortbeek LM; Tariq L; Wilson M; van Pelt W; Havelaar AH
    Int J Food Microbiol; 2015 Mar; 196():84-93. PubMed ID: 25528537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.